The collaboration will leverage RNA modification technology developed by Ethris and its co-founders, Dr. Carsten Rudolph and Prof. Christian Plank, to produce SNIM-RNA molecules ideal for use in protein replacement therapies.
Financial terms of the transaction were not revealed.
Ethris CSO and co-founder Prof. Christian Plank said the company’s partnership with Shire is based on a shared appreciation of the importance of SNIM technology.
"Under this partnership, we are aiming to develop an RNA modification and delivery technology that efficiently results in protein replacement in relevant cellular populations, providing hope to patients suffering from genetic diseases which have devastating clinical outcomes" Plank added.